Clinical Trials Browser

Phase 1 × Nivolumab × CNS × Clear all

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Phase 1 Withdrawn

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT07031765 2025-12-18

Peds CHAMP1ON

Phase 1 Active not recruiting

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma

NCT03807765 2025-12-04

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

Phase 1 Completed

Brain Neoplasms, Breast Neoplasms

NCT02914405 2025-10-22

MiniVan

Phase 1 Active not recruiting

Neuroblastoma

NCT03636477 2025-08-12

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Phase 1 Completed

21 enrolled 36 charts

Glioblastoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Active not recruiting

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT04003649 2025-07-10

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Phase 1 Recruiting

Glioblastoma

NCT04047706 2025-06-29

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1 Active not recruiting

Glioblastoma

NCT06896110 2025-06-26

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Phase 1 Enrolling by invitation

Astrocytoma, Glioblastoma

NCT04323046 2025-05-04

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Phase 1 Recruiting

Glioblastoma, Glioma

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Phase 1 Terminated

Neuroblastoma

NCT02658981 2023-10-06

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02829931 2023-01-19

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Phase 1 Completed

Glioma

NCT02526017 2022-03-09

FPA008-003

Phase 1 Completed

313 enrolled 30 charts

CNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioma, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02716948 2021-11-30

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Phase 1 Completed

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03422094 2021-10-27

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Phase 1 Terminated

Glioblastoma

NCT03707457 2020-07-02

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

Phase 1 Terminated

Glioblastoma

NCT02529072 2020-03-26

AVERT

Phase 1 Completed

6 enrolled 11 charts

Astrocytoma, Glioblastoma, Glioma

NCT02648633 2017-05-31

Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

Phase 1 Terminated

Brain Neoplasms, Glioblastoma